Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease

Summary

In clinical trials of preclinical pharmacodynamic studies, Wei Li Bai capsules has been proved to significantly improve the learning and memory ability of Alzheimer's disease model. In this study, the researchers will use a multicenter, randomized, double-blind, placebo-controlled parallel method to recruit Alzheimer's disease patients to confirm the efficacy and safety of Wei Li Bai capsules. Confirmation of drug efficacy will be observed through changes in Alzheimer's disease patients' general cognitive function scores, scores of different cognitive domains, daily living activities, and symptom severities.

Timeline

Start

2022-10-01

Primary completion

2024-11-12

Completion

2024-11-12

Outcome

Outcome not reported

Stopped (Enrollment): “Due to the inability to complete subject enrollment and follow-up as originally scheduled, coupled with funding shortages and overall strategic adjustments from the sponsor, the study was terminated on November 12, 2024.”

Drugs

Indications